HomeAI · summaries
Storia in 3 fonti
FDA expands Casgevy approval to children 2 years and older with sickle cell disease
The FDA has approved a label expansion for Casgevy to include patients aged 2 years and older with sickle cell disease and transfusion-dependent beta thalassemia. Previously approved for patients aged 12 years and older, Casgevy (exagamglogene autotemcel, Vertex Pharmaceuticals/CRISPR Therapeutics) is now the first and only gene therapy available for use in patients as young as 2 years with
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease…
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
- ·
healio.com
FDA expands Casgevy approval to children 2 years and older with sickle cell disease
The FDA has approved a label expansion for Casgevy to include patients aged 2 years and older with sickle cell disease and transfusion-dependent beta thalassemia. Previously…
- ·
medpagetoday.com
FDA Approves Sickle Cell Gene Therapy for Young Kids
Casgevy also now indicated for transfusion-dependent beta thalassemia in children 2 years and up